KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Patient-reported outcomes of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer patients (CHART): a randomized, phase 3 study.

Hongkai Wang, Shusuan Jiang, Hong Luo, Fangjian Zhou, Dalin He, Lulin Ma, Hongqian Guo, Chaozhao Liang, Tie Chong, Jun Jiang, Zhiwen Chen, Yong Wang, Qing Zou, Ye Tian, Jun Xiao, Jian Huang, Jinchao Chen, Qiang Dong, Xiaoping Zhang, Hanzhong Li, Xinfeng Yang, Jianpo Lian, Wenliang Wang, Dingwei Ye

Signal Transduct Target Ther 9(1) 351

PMID39690158
PMCIDPMC11652652
DOI10.1038/s41392-024-02064-z
发表日期2024-12-17
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

The randomized phase 3 CHART trial (NCT03520478) revealed that rezvilutamide (REZ) plus androgen deprivation therapy (ADT) in high-volume, metastatic, hormone-sensitive prostate cancer (mHSPC) significantly enhanced radiographic progression-free and overall survival than bicalutamide (BIC)-ADT. Accordingly, we examined patient-reported outcomes (PROs) results, which were exploratory endpoints in the CHART trial. The patients were randomly allocated to receive REZ-ADT or BIC-ADT in a 1:1 ratio. The PROs were evaluated with the Brief Pain Inventory-Short Form (BPI-SF) and the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaires. Both study groups displayed comparable baseline pain scores and functional status. Patients administered REZ-ADT had an extended time to progression of worst pain intensity in comparison to those treated with BIC-ADT (25th percentile, 9.2 [95% CI 7.4-16.6] vs. 6.4 months [95% CI 5.5-8.3]; HR 0.75 [95% CI 0.57-0.97]; p = 0.026). Similarly, patients received REZ-ADT exhibited a delayed time to progression of pain interference in comparison to those receiving BIC-ADT (25th percentile, 20.2 [95% CI 12.9-31.3] vs. 10.2 months [95% CI 7.4-11.1]; HR 0.70 [95% CI 0.52-0.93]; p = 0.015). Additionally, the REZ-ADT group demonstrated a prolonged delay in the deterioration of the total score on the FACT-P questionnaire (25th percentile, 12.8 [95% CI 7.4-20.3] vs. 6.0 months [95% CI 4.6-9.2]; HR 0.66 [95% CI 0.50-0.86]; p = 0.002), as well as most of the FACT-P subscale scores, in comparison to the BIC-ADT group. In conclusion, REZ-ADT is superior to BIC-ADT regarding the pain alleviation and enhancement of functional scales for high-volume mHSPC.

KM 提取结果

1 个 Figure · 3 个 KM 面板

进入结果中心
KM Figure3 个面板

Fig. 1

Kaplan–Meier curves for time to pain progression assessed by BPI-SF. a time to worst pain progression. b time to pain interference progression. c time to average pain progression

A

time to worst pain progression

Fig. 1 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台曲线 1:extreme upward reversal
查看结果
B

time to pain interference progression

Fig. 1 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme upward reversal
查看结果
C

time to average pain progression

Fig. 1 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme upward reversal
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 2Changes in pain from baseline assessed by BPI-SF. a Worst pain in past 24 h. b Pain interference. c Average pain
非 KM Figure
Fig. 3FACT-P total score. a Kaplan–Meier curve for time to functional status deterioration assessed by FACT-P total score. b Change from baseline in FACT-P total score
非 KM Figure